Targeting damaged lung tissue using compositions
The present invention relates to methods and compositions for targeting damaged lung tissue. Compositions provided feature a targeting moiety coupled to one or more other moieties, including, for example, a cross-linkable moiety, an imaging moiety, and/or one or more other targeting moieties. The methods and compositions of the invention find use, for example, in detecting and treating a pulmonary condition such as emphysema.
1 . A composition comprising a cross-linkable moiety and a targeting moiety wherein said moieties are coupled and wherein said targeting moiety targets damaged lung tissue.
2 . The composition as recited in claim 1 wherein lung tissue comprises epithelial lining fluid.
3 . The composition as recited in claim 1 wherein said composition does not comprise a polysaccharide or a carbohydrate moiety.
4 . The composition as recited in claim 1 wherein said composition does not comprise a mutant plasminogen activator-inhibitor type 1.
5 . The composition as recited in claim 1 wherein said targeting moiety targets a damage-correlated moiety.
6 . The method as recited in claim 5 wherein said damage-correlated moiety comprises a cell surface marker.
7 . The method as recited in claim 5 wherein said damage-correlated moiety comprises an ECM component.
8 . The composition as recited in claim 1 wherein said targeting moiety targets elastase.
9 . The composition as recited in claim 1 wherein said targeting moiety targets neutrophil elastase.
10 . The composition as recited in claim 1 wherein said targeting moiety comprises a protease inhibitor moiety.
11 . The composition as recited in claim 1 wherein said targeting moiety comprises an alpha-1 antitrypsin moiety.
12 . The composition as recited in claim 11 wherein said alpha-1 antitrypsin moiety is a recombinant alpha-1 antitrypsin moiety.
13 . The composition as recited in claim 1 wherein said targeting moiety comprises an elafin moiety.
14 . The composition as recited in claim 13 wherein said elafin moiety is a recombinant elafin moiety
15 . The composition as recited in claim 1 wherein said targeting moiety comprises a serpin moiety.
16 . The composition as recited in claim 15 wherein said serpin moiety is a recombinant serpin moiety
17 . The composition as recited in claim 15 wherein said serpin moiety is a secretory leukoprotease inhibitor (SLP1) moiety.
18 . The composition as recited in claim 17 wherein said secretory leukoprotease inhibitor (SLP1) moiety is a recombinant secretory leukoprotease inhibitor (SLP1) moiety.
19 . The composition as recited in claim 1 wherein said targeting moiety targets at least one matrix metalloproteinase selected from MMP-1, MMP-2, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, and MMP-9.
20 . The composition as recited in claim 19 wherein said composition does not comprise a hyaluronic acid or a salt thereof.
21 . The composition as recited in claim 1 wherein said targeting moiety targets desmosine and/or isodesmosine.
22 . The composition as recited in claim 1 wherein said targeting moiety targets CD8 and/or CD4.
23 . The composition as recited in claim 1 wherein said targeting moiety targets a smoke-related moiety.
24 . The composition as recited in claim 1 wherein said cross-linkable moiety comprises a hydroxyl group.
25 . The composition as recited in claim 1 wherein said cross-linkable moiety comprises a carboxyl group.
26 . The composition as recited in claim 1 wherein said cross-linkable moiety comprises an ester group.
27 . The method as recited in claim 1 wherein said cross-linkable moiety comprises a cyano group.
28 . The method as recited in claim 1 wherein said cross-linkable moiety comprises a thiol group.
29 . The method as recited in claim 1 wherein said cross-linkable moiety comprises a cysteine group.
30 . The method as recited in claim 1 wherein said cross-linkable moiety comprises a carbonyl group.
31 . The method as recited in claim 1 wherein said cross-linkable moiety comprises an aldehyde group.
32 . The method as recited in claim 1 wherein said cross-linkable moiety comprises a ketone group.
33 . The composition as recited in claim 1 wherein said cross-linkable moiety comprises a primary amine group and/or a secondary amine group.
34 . The composition as recited in claim 1 wherein said cross-linkable moiety comprises a lysine group.
35 . The composition as recited in claim 1 wherein said cross-linkable moiety comprises a fibrinogen and/or a fibrin.
36 . The composition as recited in claim 1 wherein said composition is less than 10 microns.
37 . The composition as recited in claim 1 wherein said composition is less than 5 microns.
38 . The composition as recited in claim 1 wherein said composition is less than 1 micron.
39 . The composition as recited in claim 1 wherein said composition further comprises an imaging moiety coupled to said targeting moiety and/or to said cross-linkable moiety.